Not Yet Recruiting BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma NCT07008053 Conditions Marginal Zone Lymphomas Locations Fujian Cancer Hospital — Fuzhou, Fujian, China The Fourth Hospital of Hebei Medical University — Shijiazhuang, Hebei, China Hunan Cancer Hospital — Changsha, Hunan, China Shandong Cancer Hospital — Jinan, Shandong, China View more locations Show fewer locations Loading locations... View Trial Details
Completed ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies NCT02362035 Conditions Blood Protein Disorders, Burkitt Lymphoma, CLL, +47 more Locations Research Site — Tucson, Arizona, United States Research Site — Los Angeles, California, United States Research Site — Denver, Colorado, United States Research Site — Washington D.C., District of Columbia, United States View all 19 locations View more locations Show fewer locations Loading locations... View Trial Details
Completed Bendamustine Plus Rituximab Versus CHOP Plus Rituximab NCT00991211 Conditions Chronic Disease, Disease Attributes, Follicular Lymphomas, +21 more Locations StiL Head Office; Justus-Liebig-University — Giessen, Germany View Trial Details
Active, Not Recruiting Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas NCT00877214 Conditions Chronic Disease, Disease Attributes, Follicular Lymphomas, +23 more Locations StiL Head Office; Justus-Liebig-University — Giessen, Germany View Trial Details
